Home 禄 Business 禄 Manufacturing
J&J makes crucial bid for Crucell
By Gilbert Kreijger |
December 9, 2010, Thursday
|
Print Edition
Print Edition
US healthcare group Johnson & Johnson made a long-awaited 1.75 billion euro (US$2.3 billion) bid for Crucell yesterday, shrugging off the Dutch biotech company's recent problems with vaccine production.
The acquisition would catapult J&J, which already owns 17.9 percent of Crucell, into the global vaccine market given the biotech firm's strong position in vaccines for childhood diseases and its focus on developing influenza vaccines.
J&J had revealed in September it was in talks to buy the outstanding shares in Crucell but quickly ran into opposition from certain key investors who believed it was worth more.
J&J said the offer was subject to fulfillment of certain conditions, including a minimum acceptance level of at least 95 percent of the shares, which will be reduced to 80 percent if certain conditions are met. It will accept shares from today till February 16.
The acquisition would catapult J&J, which already owns 17.9 percent of Crucell, into the global vaccine market given the biotech firm's strong position in vaccines for childhood diseases and its focus on developing influenza vaccines.
J&J had revealed in September it was in talks to buy the outstanding shares in Crucell but quickly ran into opposition from certain key investors who believed it was worth more.
J&J said the offer was subject to fulfillment of certain conditions, including a minimum acceptance level of at least 95 percent of the shares, which will be reduced to 80 percent if certain conditions are met. It will accept shares from today till February 16.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
